Here's an example of an oncology drug (prostate) that was recently fast tracked by the FDA.
It was stopped mid phase 3. It demonstrated a 4.8 month median OS benefit and 5.4mnth PFS. This is a lower benefit than I would have thought to stop the trial early, but due to it's low toxicity it was approved.
http://www.clinicalleader.com/doc.mvc/xtandi-gets-speedy-fda-ok-metastatic-castration-prostate-cancer-0001
- Forums
- ASX - By Stock
- IMM
- benefits of priority review and orphan status
benefits of priority review and orphan status
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $515.6M |
Open | High | Low | Value | Volume |
35.0¢ | 36.0¢ | 34.5¢ | $443.7K | 1.252M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 25847 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.5¢ | 275675 | 28 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 17073 | 0.350 |
14 | 170542 | 0.345 |
12 | 77809 | 0.340 |
7 | 56880 | 0.335 |
4 | 107400 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.355 | 275621 | 27 |
0.360 | 291200 | 34 |
0.365 | 102432 | 10 |
0.370 | 158937 | 9 |
0.375 | 180400 | 5 |
Last trade - 13.33pm 19/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |